DALY II USA/ MB-CART2019.1 for DLBCL

Clinical trial NCT04792489 · RECRUITING

Trial details

NCT number: NCT04792489
Sponsor: Miltenyi Biomedicine GmbH
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Refractory Diffuse Large B Cell Lymphoma (DLBCL)Relapsed Diffuse Large B Cell Lymphoma High Grade B-cell Lymphoma (HGBCL)Primary Mediastinal B-cell Lymphoma (PMBCL)Transformed Lymphoma Central Nervous System Lymphoma Mantle Cell Lymphoma (MCL)Richter Transformation Transplant-ineligible 2nd Line DLBCL

Start date: 2021-05-25
Primary completion: 2026-12-31
Enrollment: 315

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.